Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.
Women with AMI in Sweden had a higher excess mortality compared with men, which was reduced after adjustment for the use of guideline-indicated treatments.
Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.
In a longitudinal 40-years follow-up, the impact of 8 traditional CV risk factors on CVD declined with aging, with the exception of LDL-c for MI, and BMI and fasting glucose for HF.
Beta-blockers improve left ventricular systolic function and reduce CV morbidity and mortality in heart failure patients with mid-range ejection fraction compared to placebo.
View expert session focused on the latest developments in anticoagulation treatment.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
A meta-analysis shows that the relative benefit of BP-lowering is evident when baseline SBP is ≥140mmHg, but not if it is <140 mmHg, particularly in primary prevention.
In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.
Download a free copy of this review on CV risk management in Russia. The documents discusses the current situation and considers how CVRM may be improved in Russia.
Ex vivo LDL-receptor expression is inversely associated with the plasma levels of LDL-c and apoB in HoFH patients before and after treatment with evolocumab.